We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+66.02%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$388M
Cap. Flow
+$189M
Cap. Flow %
25.34%
Top 10 Hldgs %
93.39%
Holding
31
New
7
Increased
2
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$223M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$36.4M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$9.04M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$8.87M
5
CYTK icon
Cytokinetics
CYTK
+$7.27M

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$28.8M
2
IMGN
Immunogen Inc
IMGN
+$19.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$14.9M
4
ROIV icon
Roivant Sciences
ROIV
+$14.4M
5
ARGX icon
argenx
ARGX
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
26
Roivant Sciences
ROIV
$24.3B
– –
-1,279,700
Closed -$14.4M
SCYX icon
27
SCYNEXIS
SCYX
$36M
– –
-69,444
Closed -$1.24M
SLRN
28
DELISTED
ACELYRIN
SLRN
– –
-1,370,951
Closed -$10.2M
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
– –
-714,285
Closed -$4.64M
KRTX
30
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-47,000
Closed -$14.9M
IMGN
31
DELISTED
Immunogen Inc
IMGN
– –
-659,928
Closed -$19.6M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Decheng Capital held 31 positions worth $746M, up 108% from $358M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Decheng Capital deployed $189M of net new capital in Q1 2024, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was CG Oncology: 5,458,810 shares worth $240M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was 10x Genomics, an estimated $7.19M trimmed.

  • Decheng Capital's largest Q1 2024 buy was CG Oncology: 5,458,810 shares worth $240M.
  • Decheng Capital added most to Alpine Immune Sciences Inc in Q1 2024, an estimated $36.4M increase.
  • Decheng Capital's biggest Q1 2024 reduction was 10x Genomics, cutting an estimated $7.19M.
  • Decheng Capital fully exited Pacific Biosciences in Q1 2024, selling an estimated $28.8M.
  • Decheng Capital's ten largest holdings make up 93% of its $746M portfolio in Q1 2024.
  • Decheng Capital opened 7 new positions and closed 9 in Q1 2024.
  • Decheng Capital's portfolio value rose 108% quarter-over-quarter to $746M.

Based on Decheng Capital's 13F filing for Q1 2024, filed 14 May 2024.